Secukinumab | Anti-IL-17A human monoclonal antibody | Severe hypersensitivity reactions to the active substance or to any of the excipients Clinically important, active infection (e.g. active tuberculosis). | Subcutaneous application, maintenance dosing every 4 weeks; Washout period 11 - 19 weeks |
Tildrakizumab | Anti IL-23 humanized IgG1/k monoclonal antibody | Clinically important active infection (e.g. active tuberculosis) | Subcutaneous application, maintenance dosing four times per year |
Ustekinumab | Anti-IL-12/23 human monoclonal antibody | Clinically important active infection (e.g. active tuberculosis. | Subcutaneous application, maintenance dosing every 12 weeks; Washout period 9 - 15 weeks |